Table 5.
Inhaled loxapine in subjects with asthma or chronic obstructive pulmonary disease – pulmonary findings
| Outcome | Asthma | COPD | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Placebo (N = 26) | Loxapine 10 mg (N = 26) | Placebo (N = 27) | Loxapine 10 mg (N = 26)* | |||
|
|
|
|||||
| n (%) | n (%) | NNH (95% CI) | n (%) | n (%) | NNH (95% CI) | |
| ≥10% reduction in FEV1 | 3 (12) | 22 (85) | 2 (2–2) | 18 (67) | 20 (80) | 8 (NS) |
| ≥20% reduction in FEV1 | 1 (4) | 11 (42) | 3 (2–6) | 3 (11) | 10 (40) | 4 (2–16) |
| Any airway adverse event | 3 (12) | 14 (54) | 3 (2–6) | 3 (11) | 5 (19) | 13 (NS) |
| Adverse event of bronchospasm | 1 (4) | 7 (27) | 5 (3–23) | 1 (4) | 0 | NA |
| Albuterol use | 3 (12) | 14 (54) | 3 (2–6) | 4 (15) | 6 (23) | 13 (NS) |
Note:
*
Spirometry data not available for one subject, thus N = 25.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, volume of air exhaled in the first second of a forced exhalation starting from a position of full inspiration; NA, not applicable; NNH, number needed to harm; NS, not significant.